News
This twice-a-year shot to prevent HIV could stop transmission — if people can get it
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option.
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo from company Gilead Sciences, remained ...
IFLScience on MSN2h
Revolutionary Drug That's “Closest Thing” To HIV Vaccine Gets FDA ApprovalThe Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that has been shown to act as ...
The New Times on MSN1h
WHO guidelines for 6-month HIV prevention drug to be released in KigaliThe approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...
The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...
The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback